Findings from the phase 3 VOLGA trial support the FDA approval of perioperative durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
|Videos|June 10, 2019
Dr. Patricia Eifel on the Shifts in Cervical Cancer Treatment
Author(s)Patricia J. Eifel, MD
Cancer Network spoke with Patricia Eifel, MD, of the University of Texas MD Anderson Cancer Center, about the current shifts in the treatment of cervical cancer.
Advertisement
Cancer Network spoke with Patricia Eifel, MD, of the University of Texas MD Anderson Cancer Center, about the current shifts in the treatment of cervical cancer.
Advertisement
Related to this article
Adding trotabresib to chemoradiotherapy did not improve progression-free or overall survival and was associated with more dose reductions and interruptions.
The ACS now recommends biennial PSA screening for average-risk men aged 50 to 69 years and annual screening from age 45 for Black men.
Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
2
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
3
What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance
4
Managing Hypoxia, Anemia, and Cardiac Toxicity With Belzutifan Plus Lenvatinib
5